NAD+ precursor · Fact sheet

Nicotinamide mononucleotide

Also known as NMN · beta-NMN

NMN can affect NAD-related biomarkers in small human trials, but it is not an FDA-approved drug for anti-aging, energy, sleep, muscle performance, or metabolic disease. The clinical significance of reported signals remains uncertain.

Not FDA approvedEarly human evidence

What is Nicotinamide mononucleotide?

NMN is a naturally occurring nucleotide derivative used by cells to produce NAD+.

It is related to, but not interchangeable with, nicotinamide riboside or NAD+ itself.

Benefits & claims

Animal studies made NMN prominent in healthy-aging research, and small human trials have since examined metabolic, walking, sleep, and body-composition endpoints.

Most studies are short, use modest sample sizes, and measure many outcomes, so replication and clinical relevance matter.

What the evidence supports

  • Small trials report increased NAD-related metabolites and some secondary signals in physical function or sleep.
  • A controlled trial of a pharmaceutical NMN formulation found target engagement but did not establish a broad physiological rejuvenation effect.
Research areas
  • NAD+ metabolism and aging biomarkers
  • Walking and physical performance
  • Sleep and fatigue
  • Insulin sensitivity and body composition

Dosage & frequency

Human study context

Human oral NMN studies have tested particular products and measured biomarkers or short-term function. There is no FDA-approved NMN anti-aging regimen.

Randomized older-adult NMN study

Older adults in the published study

Amount
250 mg/day
Frequency
Daily for twelve weeks
Route studied or labeled
Oral

The primary stepping-test outcome did not significantly differ; secondary findings do not establish a longevity prescription.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • NMN is a NAD precursor; it is not direct NAD+ infusion or nicotinamide riboside.

Interactions & precautions

  • Short oral NMN studies do not establish compatibility with every medicine or other NAD precursor combination.

What is still unresolved

  • A durable clinical benefit, optimal schedule, and long-term safety profile remain uncertain.

Side effects & risks

  • Short studies cannot rule out uncommon or long-latency harms.
  • Commercial products may not match the identity, purity, or stability of material used in a clinical trial.
  • The implications of long-term NAD-pathway manipulation in cancer, inflammatory disease, or other conditions are unresolved.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

Human randomized trials are emerging and show biochemical effects, but results for walking, strength, insulin sensitivity, sleep, and other functional outcomes are not yet consistent enough for broad claims.

Studies

What do the human studies show?

Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.

Who took part, what was measured, and what the study found
Study and peopleQuestion and follow-upResult and limits
MIB-626 NMN study

Adults aged ≥45 with overweight or obesity

30 participants (actual)

Randomized placebo-controlled trial; human

Nicotinamide mononucleotide versus Placebo

28 days

Primary: Safety, NAD metabolism and physiological measures; endpoint hierarchy not extracted

Phase: Not listed in this summary
Registry status: Not assessed
Registry results: Not assessed
Publication: published; peer reviewed

Circulating NAD increased; strength, fatigability, aerobic capacity and stair-climbing changes did not differ significantly.

Cannot tell us: Multiple short-term outcomes; no inference about lifespan. This formulation cannot represent every NMN product.

Safety, uncertainty, and source details

Reported adverse events were similar between groups over 28 days.

Limited to the studied population, formulation and follow-up.

Funding/conflicts: Not confirmed in this summary; check the full paper.

Source checked: 2026-09-18. Independent clinical review: not completed.

What these results can and cannot tell us

Did the MIB-626 NMN study establish better physical function?

The selected short trial reported target engagement but no significant differences in the listed physical performance measures.

Limit: No conclusion about lifespan, every NMN formulation or every population follows.

Check the sources: MIB-626: NAD augmentation in adults (checked 2026-09-18)

Related, not equivalent: NAD+ · Nicotinamide riboside.

Compare research questions · Submit a source-based correction

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

Little perceived benefit over about 100 days

An active adult described little clear benefit from NMN with TMG. They later felt somewhat more energetic after a change, while explicitly questioning whether that was placebo or an ordinary good day.

Reported use in this account

Product
NMN powder taken in water
Amount
1 g initially; 1.5 g on the morning of the tentative later change
Frequency
Every morning during the initial period
Route
Oral, in a glass of water
Duration
Almost 100 days

Other exposures described: TMG; CBD oil; Creatine; Collagen, magnesium, vitamin D/K2 and fish oil; Regular sport and activity

CBD, creatine and several other supplements were also used. The tentative later change does not establish NMN efficacy or an anti-aging effect.

Read the original account
Mixed account · personal report

Fatigue despite a perceived skin improvement

An author described marked fatigue and longer sleep while taking NMN with other supplements, despite thinking their skin looked better. A follow-up described insomnia after changing the timing of NMN and TMG.

Reported use in this account

Product
Product described as NMN
Amount
175 mg in the initial morning account; a later reply also describes 175 mg before bed
Frequency
Morning initially; morning and bedtime in the follow-up
Route
Not specified clearly
Duration
Not specified clearly

Other exposures described: B vitamins; Methylfolate; TMG; Fish oil

B vitamins, methylfolate, TMG and fish oil were also used. Neither a genetic explanation nor causation was clinically verified.

Read the original account
Mixed account · personal report

More perceived energy, with initial insomnia and earlier waking

A person described initial stimulation and difficulty falling asleep, followed later by less of that effect but persistent earlier waking and perceived improvements in exercise and daytime energy.

Reported use in this account

Product
NMN powder taken with water
Amount
Around 500 mg, as estimated by the author
Frequency
More or less daily, with vacations off, in the morning
Route
Oral, with a glass of water
Duration
Since February 2023 at the update; exact elapsed duration not stated in the text

Other exposures described: B-complex with magnesium and vitamin D; Creatine; Coffee; A cannabis edible tried later for sleep

Other lifestyle factors and coffee use were discussed. Subjective energy and sleep changes do not establish reversal of aging or a durable clinical benefit.

Read the NMN follow-up

Approval status

NMN has no FDA-approved drug indication for aging or any consumer wellness goal. Product-specific U.S. marketing status is a separate legal question from whether a health claim is clinically proven.

No FDA-approved drug use

NMN has small human trials and unresolved U.S. product-status questions, but no FDA-approved drug indication for aging, sleep, energy, or metabolic disease.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether any signal replicates in larger and more diverse populations
  • Whether changes in biomarkers translate into fewer diseases or better function
  • Long-term safety
  • Which observed differences reflect NMN rather than chance across many measured endpoints

Summary

NMN has early human studies, without established anti-aging, sleep, metabolic or performance benefits.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedRandomized NMN trial in older adults

    Controlled study of walking, sleep, and related endpoints that requires replication and cautious interpretation.

  2. pubmedRandomized trial of the NMN formulation MIB-626

    Human target-engagement and physiological-outcomes trial in adults with overweight or obesity.

  3. pubmedClinical trial of NMN in healthy adults

    Small placebo-controlled study assessing short-term safety and selected outcomes.

  4. fdaFDA: what ‘FDA approved’ does and does not mean

    FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.

How we assess sources · Suggest a correction